Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.
Matthew S Davids, Asher Chanan-Khan, Sikander Ailawadhi...
https://pubmed.ncbi.nlm.nih.gov/41109219/Actively Recruiting
Led by Ascentage Pharma Group Inc. · Updated on 2025-04-10
144
Participants Needed
9
Research Sites
86 weeks
Total Duration
Researchers are evaluating lisaftoclax, a drug being studied alone or combined with other therapies, for patients with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The main goals are to assess the safety, tolerability, identify dose-limiting toxicities DLT, and determine the maximum tolerated dose MTD or recommended phase 2 dose RP2D of lisaftoclax. This research focuses on patients who need treatment after prior therapies and aims to better understand the dosing and safety profile of this drug. The trial is conducted in two parts, each including a ramp-up period, dose escalation, and dose expansion phases. The ramp-up involves gradually increasing doses of lisaftoclax from 20 mg to up to 1,000 mg daily over several days, depending on the assigned dose level. Part 1 studies lisaftoclax alone at various doses 400 mg, 600 mg, 800 mg, and 1,000 mg, while Part 2 evaluates lisaftoclax combined with rituximab or acalabrutinib through a dose escalation and expansion design to further assess safety and anticancer activity. Participants will be closely monitored with assessments including safety evaluations and toxicity checks over a 42-day period to identify dose-limiting toxicities and maximum tolerated dose. The study requires patients to attend visits for treatment administration, follow-up examinations, and to provide informed consent. Researchers will track outcomes related to safety and dosing to inform future studies. The trial is designed for adults aged 18 to 85 with relapsed or refractory CLLSLL, and participants will be followed throughout the study duration as per protocol.
CONDITIONS
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
L
Laura Glass
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Ascentage Pharma Group Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Lisaftoclax 400 mg daily | Lisaftoclax 600 mg daily | Lisaftoclax 800 mg daily | Lisaftoclax 1000 mg daily |
|---|---|---|---|---|
| What it is | Lisaftoclax administered as a 400 mg oral daily dose in adults with relapsed or refractory CLL/SLL. | Lisaftoclax administered as a 600 mg oral daily dose in adults with relapsed or refractory CLL/SLL. | Lisaftoclax administered as an 800 mg oral daily dose in adults with relapsed or refractory CLL/SLL. | Lisaftoclax administered as a 1000 mg oral daily dose in adults with relapsed or refractory CLL/SLL. |
| Role in trial | Lowest dose escalation cohort for evaluating dose-limiting toxicity and maximally tolerated dose. | Intermediate dose escalation cohort for evaluating dose-limiting toxicity and maximally tolerated dose. | Higher dose escalation cohort for evaluating dose-limiting toxicity and maximally tolerated dose. | Highest dose escalation cohort for evaluating dose-limiting toxicity and maximally tolerated dose. |
| Primary use being studied | Studied to determine safety, tolerability, and preliminary activity of Lisaftoclax at 400 mg daily in relapsed/refractory CLL/SLL. | Studied to determine safety, tolerability, and preliminary activity of Lisaftoclax at 600 mg daily in relapsed/refractory CLL/SLL. | Studied to determine safety, tolerability, and preliminary activity of Lisaftoclax at 800 mg daily in relapsed/refractory CLL/SLL. | Studied to determine safety, tolerability, and preliminary activity of Lisaftoclax at 1000 mg daily in relapsed/refractory CLL/SLL. |
| How it is given | Oral daily dosing of Lisaftoclax, starting at 400 mg, with ramp-up titration based on safety and tolerability monitoring. | Oral daily dosing of Lisaftoclax, starting at 600 mg, with ramp-up titration based on safety and tolerability monitoring. | Oral daily dosing of Lisaftoclax, starting at 800 mg, with ramp-up titration based on safety and tolerability monitoring. | Oral daily dosing of Lisaftoclax, starting at 1000 mg, with ramp-up titration based on safety and tolerability monitoring. |
| Evidence status for this dose | This dose is being studied in a phase 1 dose-finding clinical trial for safety, pharmacokinetics, and preliminary signals of clinical activity; no conclusive results are available yet. | This intermediate dose is under clinical evaluation to determine its safety and optimal dose; evidence is limited to early-phase findings, and final results are pending. | Evaluation is ongoing in this higher dose cohort to assess safety and activity signals; no mature clinical activity data is available to date. | Currently being studied for dose-limiting toxicities and maximally tolerated dose determination; evidence is preliminary and results will inform later studies. |
| Important limitations | This is an early-phase dose-escalation cohort with a small sample size and short follow-up; long-term safety and efficacy remain unknown. | Interim results are based on limited numbers and follow-up, and this intermediate dose may not reflect final dosing recommendations or long-term outcomes. | Clinical experience at this higher dose is limited to early-phase study data, and findings may not be generalizable to routine practice. | The highest dose cohort is being tested for tolerability and safety, but patient numbers are few and clinical outcomes are not yet established. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 3 to 8 days depending on dose level
Participants undergo a ramp-up dosing schedule where lisaftoclax is administered daily in increasing doses until the target dose is reached.
Daily visits for up to 8 days
Duration - Up to 42 days per cycle or until disease progression or discontinuation
Participants receive lisaftoclax as monotherapy or in combination with rituximab or acalabrutinib at assigned dose levels to evaluate safety and anticancer activity.
Visits scheduled according to treatment cycles
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Matthew S Davids, Asher Chanan-Khan, Sikander Ailawadhi...
https://pubmed.ncbi.nlm.nih.gov/41109219/Ascentage Pharma Group Inc.
Lead Sponsor